deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT03452397

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

Sponsor: Oyster Point Pharma, Inc.

Conditions Dry Eye Disease
Interventions 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL) 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL) 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL) Placebo (vehicle) nasal spray
Updated 11 times since 2018 Last updated: Nov 16, 2021 Started: Feb 27, 2018 Primary completion: Apr 27, 2018 Completion: Apr 27, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Dry Eye Disease and is currently completed. Oyster Point Pharma, Inc. leads this study, which shows 11 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshotRecruiting~Apr 2018 – ~May 2018 · 30 days · monthly snapshotRecruiting~May 2018 – ~Jun 2018 · 31 days · monthly snapshotActive Not Recruiting~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotActive Not Recruiting~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshotCompleted~Aug 2018 – ~Jun 2019 · 10 months · monthly snapshotCompleted~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshotCompleted~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshotCompleted~Jan 2022 – ~Jul 2024 · 30 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jan 2022 [monthly]

    Completed PHASE2

  5. Jun 2019 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 6 earlier versions

  1. Aug 2018 — Jun 2019 [monthly]

    Completed PHASE2

  2. Jul 2018 — Aug 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  4. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE2

  6. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

    First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Oyster Point Pharma, Inc.
Data source: Oyster Point Pharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations